Role of CD44 in tumour progression and strategies for targeting
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
CD44 or hyaluronan receptor is a transmembrane receptor associated with aggressive tumour growth, proliferation, and metastasis. In normal physiology, this receptor has a crucial role in cell adhesion, inflammation, and repair processes. However, many tumour cells over-express this receptor and abuse it to become progressive and perpetual units. The article comments from common functioning of the CD44 receptor, to its diabolic multi-dimensional effects in promotion of malignant cells. It also illuminates the relations of CD44 endorsed processes with other biomolecular events in cancer progression. In an end, the review focuses comprehensively at ongoing researches to exploit the CD44 over-expression as a probable target in treatment, management, and diagnosis of malignancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yu, Q., & Stamenkovic, I. (2000) · Genes & Development · doi:10.1101/gad.14.2.163 · Cited by 1,754
Heparan sulphate proteoglycans fine-tune mammalian physiology
Bishop, J. R., Schuksz, M., & Esko, J. D. (2007) · Nature · doi:10.1038/nature05817 · Cited by 1,631
Macrophages Regulate the Angiogenic Switch in a Mouse Model of Breast Cancer
Lin, E. Y., Li, J.-F., Gnatovskiy, L., Deng, Y., Zhu, L., Grzesik, D. A., Qian, H., Xue, X.-N., & Pollard, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1278 · Cited by 1,074 · cited 1×
“Presence of CD44 receptors in the stroma of cancer cells and tumour accelerate the recruitment of monocytes and tumour associated macrophages, which release the angiogenic and lymphangiogenic growth factors (Schoppmann et al., 2002; Lin et al., 2006).”
BackgroundSchoppmann, S. F., Birner, P., Stöckl, J., Kalt, R., Ullrich, R., Caucig, C., Kriehuber, E., Nagy, K., Alitalo, K., & Kerjaschki, D. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64255-1 · Cited by 794
Jain, A., Jain, S. K., Ganesh, N., Barve, J., & Beg, A. M. (2010) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2009.03.002 · Cited by 214 · cited 1×
“HA-chitosan nanoparticles of oxalipaltin were also demonstrated to have better therapeutic response in murine colon carcinoma model (Jain et al., 2010).”
Background
Cited by
Cancer metastases: challenges and opportunities
Guan, X. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.07.005 · Cited by 952
Stem cell programs in cancer initiation, progression, and therapy resistance
Huang, T., Song, X., Xu, D., Tiek, D., Goenka, A., Wu, B., Sastry, N., Hu, B., & Cheng, S.-Y. (2020) · Theranostics · doi:10.7150/thno.41648 · Cited by 524
The Role of CD44 in Disease Pathophysiology and Targeted Treatment
Jordan, A. R., Racine, R. R., Hennig, M. J. P., & Lokeshwar, V. B. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00182 · Cited by 275
Therapies targeting cancer stem cells: Current trends and future challenges
Dragu, D. L. (2015) · World Journal of Stem Cells · doi:10.4252/wjsc.v7.i9.1185 · Cited by 257
Gelatine Methacrylamide-Based Hydrogels: An Alternative Three-Dimensional Cancer Cell Culture System
Kaemmerer, E., Melchels, F. P. W., Holzapfel, B. M., Meckel, T., Hutmacher, D. W., & Loessner, D. (2014) · Acta Biomaterialia · doi:10.1016/j.actbio.2014.02.035 · Cited by 219
“CD44 is a key factor in tumour growth and metastasis [39].”
Background
Metadata
- Authors
- Negi, L. M., Talegaonkar, S., Jaggi, M., Ahmad, F. J., Iqbal, Z., & Khar, R. K.
- Venue
- Journal of Drug Targeting
- Publisher
- Informa UK Limited
- Published
- 2012-07-04
- Volume
- 20
- Issue
- 7
- Pages
- 561-573
- ISSN
- 1026-7158 (ISSN-L)
- 1061-186X
- 1029-2330
- OpenAlex
- W1967682615
- Cited by
- 108
- References
- 5
- FWCI
- 5.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.